‘Keep Planning For No-Deal Brexit,’ UK Govt Tells Pharma As Chaos Grows
Executive Summary
Amid the growing mayhem in parliament over the Brexit process, life science companies have been advised to continue preparing for the possibility that the UK might leave the EU without a deal at the end of next week.
You may also be interested in...
UK Offers Pharma Firms Ferry Tickets To Avoid No-Deal Brexit Supply Disruptions
The UK health department says it has purchased ferry tickets that pharmaceutical companies can buy in order to transport their medicines and other product using alternative shipping routes between EU and UK ports in the event of a no-deal Brexit. It has also updated companies on how they can access additional warehousing space for medicine stockpiles.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.